Cody Tranbarger
Cody Tranbarger is a biotech entrepreneur who founded Mithril MedicineMithril MedicineMithril Medicine is a biotechnology company based in Cambridge, Massachusetts, developing multispecific antibodies for patients with rare genetic diseases.Open the full entry, a one-person company developing antibody therapies for genetic diseases that used Claude to advance programs for two rare forms of muscular dystrophy. AnthropicAnthropicAnthropic is an artificial intelligence research and product company founded in 2021 that develops the Claude models, assistant, and tools such as Claude Code, and operates as a public benefit corporation. Dario Amodei and Daniela Amodei are its co-founders, and its research covers model safety, interpretability, and steerability.Open the full entry acquired the company in 2026, and he continued the research at Anthropic.
Contents6 sections
Key facts
Founding: Mithril Medicine as a One-Person Company
He was Mithril’s only full-time employee, and the company developed a promising muscular dystrophy treatment within 18 months.[1]
He used Claude to organize contracts, logistics and experiments with 11 external labs.[2]
Mithril was backed by Atlas Venture and had operated in stealth before the acquisition.[3]
July–October 2026: Anthropic Acquires Mithril Medicine
Anthropic completed its acquisition of Mithril Medicine, the company he founded, in July 2026 and disclosed it in late October; terms were not disclosed.[4]
After joining Anthropic, he continued the research.[2]
In October 2026 he was corresponding author of a related technical report.[5]
Anthropic added Mithril’s two muscular dystrophy programs to its drug discovery work.[6]
He said he joined Anthropic to give the programs continuity and more resources, to learn how many programs one person can run, and to spread the model across biopharma.[7]
October 27, 2026Revealing the “Professor Oak” Persona
In posts on X he identified himself as the person behind the pseudonymous biotech commentary account “Professor Oak” (@Prof_Oak_).[8]
Views: “Pipeline-in-a-Person”
He has put forward a “Pipeline-in-a-Person” thesis: that a single scientist with enough AI support could run several drug programs in parallel.[7]
By his estimate, using Claude cut the time to prepare an initial research strategy for a new drug program from one or two months to two or three days.[1]
Planned Timeline
If the candidates hold up, a drug could enter human trials as early as late 2028.[9]
Sources
- Anthropic acquires one-person biotech startup that used Claude to develop promising muscular dystrophy treatment in 18 months (opens in a new window)
- Early progress on accelerating drug development with Claude (opens in a new window)
- Anthropic's latest biotech buy is a one-man stealth startup run by a pseudonymous Twitter poster (opens in a new window)
- Anthropic Bought A One-Person Biotech That Ran A Drug Program With Claude (opens in a new window)
- Preclinical Characterization of a Bispecific Bridging Antibody for the Treatment of LAMA2-Related Congenital Muscular Dystrophy (opens in a new window)
- Anthropic Acquires Mithril Medicine to Expand Drug Discovery Work (opens in a new window)
- Anthropic Acquires One-Person Drug Discovery Startup Mithril Medicine Founded By Cody Tranbarger (opens in a new window)
- Anthropic acquires Mithril Medicine to run drug programs with Claude (opens in a new window)
- Anthropic buys a one-person biotech and starts its own drug programmes (opens in a new window)